Unknown

Dataset Information

0

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide.


ABSTRACT: Evofosfamide is a cytotoxic small-molecule prodrug preferentially activated under hypoxic conditions. The cytotoxicity of evofosfamide impacted the generation of in vitro drug-drug interaction (DDI) data, especially in vitro induction results. Therefore, a novel physiologically based pharmacokinetic (PBPK) approach was used, which involved available in vitro and clinical data of evofosfamide and combined it with induction data from the prototypical cytochrome P450 (CYP)3A inducer rifampicin. The area under the concentration-time curve (AUC) ratios of midazolam were above 0.80, indicating that induction of CYP3A by evofosfamide administered weekly is unlikely to occur in humans. Moreover, static and PBPK modeling showed no clinically relevant inhibition via CYP2B6, CYP2D6, and CYP3A4. In conclusion, PBPK models were used to supplement in vitro information of a cytotoxic compound. This approach may set a precedent for future studies of cytotoxic drugs, potentially reducing the need for clinical DDI studies and providing more confidence in the clinical use of approved cytotoxic compounds for which DDI information is sparse.

SUBMITTER: Lupfert C 

PROVIDER: S-EPMC6310869 | biostudies-other | 2018 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide.

Lüpfert Christian C   Dyroff Martin M   von Richter Oliver O   Gallemann Dieter D   El Bawab Samer S   Dolgos Hugues H   Jung Don D   Hecht Stefan S   Johne Andreas A  

CPT: pharmacometrics & systems pharmacology 20181031 12


Evofosfamide is a cytotoxic small-molecule prodrug preferentially activated under hypoxic conditions. The cytotoxicity of evofosfamide impacted the generation of in vitro drug-drug interaction (DDI) data, especially in vitro induction results. Therefore, a novel physiologically based pharmacokinetic (PBPK) approach was used, which involved available in vitro and clinical data of evofosfamide and combined it with induction data from the prototypical cytochrome P450 (CYP)3A inducer rifampicin. The  ...[more]

Similar Datasets

2021-02-26 | PXD024158 | Pride
| S-EPMC7320947 | biostudies-literature
| S-EPMC8082684 | biostudies-literature
| S-EPMC6851657 | biostudies-literature
| S-EPMC7902086 | biostudies-literature
| PRJEB38781 | ENA
| S-EPMC5980577 | biostudies-literature
| S-EPMC7679072 | biostudies-literature
| S-EPMC10088082 | biostudies-literature
| S-EPMC9369352 | biostudies-literature